US Patent

US8652776 — Prediction of QT prolongation based on SNP genotype

Method of Use · Assigned to Vanda Pharmaceuticals Inc · Expires 2030-08-31 · 4y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method for predicting and treating QT prolongation in patients based on their genetic makeup.

USPTO Abstract

The present invention relates to the prediction of QT prolongation following administration of a compound capable of increasing an individual's QT interval based on the individual's genotype at one or more single nucleotide polymorphism (SNP) loci and to the treatment of a patient based on such prediction.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-1685 — Fanapt
U-1685 — Fanapt
U-1685 — Fanapt
U-1685 — Fanapt
U-1685 — Fanapt
U-1685 — Fanapt
U-1685 — Fanapt

Patent Metadata

Patent number
US8652776
Jurisdiction
US
Classification
Method of Use
Expires
2030-08-31
Drug substance claim
No
Drug product claim
No
Assignee
Vanda Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.